San Rocco Therapeutics

Executive Summary

San Rocco Therapeutics is a privately-held biotechnology company headquartered in Cambridge, Massachusetts, focused on developing gene therapies for life-threatening rare diseases, with an initial emphasis on hemoglobinopathies such as Sickle Cell Disease and Beta Thalassemia. Founded in 2021, the company leverages pioneering research in fetal hemoglobin reactivation to create potentially curative treatments that are both effective and affordable for underserved patient populations. By targeting the root cause of these blood disorders, San Rocco aims to address the significant unmet medical need and reduce the burden on healthcare systems. The company's approach involves delivering a therapeutic gene to restore fetal hemoglobin expression, thereby compensating for defective adult hemoglobin. With a strong scientific foundation and a clear mission, San Rocco represents a compelling opportunity in the gene therapy space, though it remains in early stages of development.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Gene Therapy Candidate70% success
• Q4 2026Preclinical Data Presentation at Major Conference80% success
• Q2 2026Series A Financing Announcement60% success